Although post-transplant donor lymphocyte infusions might induce remissions in few patients via the induction of a graftversus-leukemia effect, 1 refractory relapse of B-precursor acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a dismal prognosis. Morphological disease 2 or persistent minimal residual disease (MRD) levels of 410 À4 leukemic blasts 3 before allogeneic HSCT have been shown to be associated with a high risk of relapse after transplantation and a poor outcome. Despite the use of recently introduced chemotherapeutic agents for refractory leukemia, 4 patients who relapse after allogeneic HSCT often have refractory disease and are particularly susceptible to chemotherapy-related toxicity.
T-cell engaging antibodies are a novel strategy for treatment of lymphoma and leukemia. 5 Such bispecific antibodies are designed to transiently engage primed cytotoxic effectormemory T lymphocytes for the lysis of target cells. By using the T-cell engaging CD19/CD3-bispecific antibody blinatumomab, partial and complete remissions (CRs) in patients with relapsed B cell non-Hodgkin lymphomas, 6 and elimination of chemorefractory residual leukemic blasts in bone marrow of the adult patients with MRD-positive B-precursor ALL were observed. 7 Although in these patients with B-precursor ALL, the blinatumomab-engaged cytotoxic T cells were patient derived, blinatumomab had so far not been administered in pediatric patients or in any patients after allogeneic HSCT, a condition in which the engaged T cells are donor derived.
After informed consent from the care givers and patients' assent were obtained, we treated three patients with blinatumomab, all of whom had post-transplant relapsed B-precursor ALL. The compassionate use of blinatumomab in all three patients was approved by the institutional review board and by the responsible local regulatory authority (Regierungsbezirk Oberbayern, Munich, Germany). Blinatumomab was provided by Micromet (Munich, Germany). Apart from a single prednisone dose of 2 mg/kg at the first day before the continuous intravenous infusion of blinatumomab, no other concomitant antileukemic drugs were administered.
The first patient was a 7-year-old boy, who was diagnosed in 2004 with high-risk B-precursor ALL and was treated according to the COALL protocol. He experienced a bone marrow relapse in June 2006 and was treated according to the ALL-REZ BFM 2002 protocol in the S3 arm. After two cycles of chemotherapy, the patient had persistent disease. A complete second remission was achieved after three courses of clofarabine. In February 2007, he received an allogeneic HSCT from a 9 out of 10 human leukocyte antigen (HLA) allele-matched-unrelated donor after conditioning with total body irradiation and etoposide. At 1 year after allogeneic HSCT, he experienced another bone marrow relapse and received subsequent chemotherapy including one cycle of clofarabine/cyclophosphamide/etoposide, two cycles of amsacrine/etoposide/prednisone and one cycle of melphalan/ cytarabine. At 4 weeks after the last chemotherapy cycle with melphalan (20 mg/m 2 ) and cytarabine (2 g/m 2 /day Â 3 days), a bone marrow aspiration revealed persistent disease with 3% leukemic blasts quantified by flow cytometry. Apart from the leukemic cell population, the residual hematopoiesis including T lymphocytes was donor derived. The patient was then treated with blinatumomab at 15 mg/m 2 /day for 5 weeks by continuous intravenous infusion.
The analysis of lymphocyte populations before and during treatment the with blinatumomab showed an expansion of CD3 þ T lymphocytes with a peak at day 8 of the treatment (Figure 1a ). Concomitant analysis of peripheral lymphocytes showed persistent 100% donor chimerism. A bone marrow analysis at day 10 of treatment revealed a CR with an MRD level of o10
À4
, which is below the quantitative detection limit. Bone marrow analysis at the end of the treatment confirmed the absence of leukemic blasts. The analysis of MRD before, during and after the treatment with blinatumomab is depicted in Figure 2a . Apart from initial transient and completely reversible mild ataxia within the first 5 days of treatment (NCI Common Terminology Criteria for Adverse Events (CTCAE)1 2), no other side effects were observed. Despite the impressive expansion of donor-derived allogeneic T lymphocytes, no signs of graftversus-host disease were seen. In September 2008, 2 weeks after the end of treatment with blinatumomab and while in MRD-negative CR, the patient underwent a second allogeneic HSCT from his haploidentical mother using a nonmyeloablative preparative regimen consisting of clofarabine, thiotepa and melphalan. 8 As of August 2010, 23 months after haploidentical transplantation, the patient remains in continuous MRD-negative CR.
The second patient was diagnosed with B-precursor ALL at the age of 12 and treated according to the national protocol ALL-BFM 2000 medium risk group. At 32 months later, he experienced a bone marrow relapse and received intensive multidrug chemotherapy according to the ALL-REZ BFM 2002 protocol. Because of the persistent MRD after salvage induction therapy (410 À3 ), allogeneic HSCT was performed from a 10 out of 10 HLA allele-matched unrelated donor after conditioning therapy with total body irradiation and etoposide. At 21 months later, the patient experienced a second bone marrow relapse. At 11 months after successful remission induction, he experienced
Letters to the Editor a third bone marrow relapse and received a variety of antileukemic agents including vincristine/prednisone reinduction pulses, prednisone/etoposide cycles, finally biweekly vincristine/idarubicin pulses with persistent overt disease (90% infiltration with leukemic blasts in bone marrow and 23% leukemic blasts in peripheral blood). Because of the refractory disease, blinatumomab was started 2 weeks after the last chemotherapy cycle at 15 mg/m 2 /day, administered as continuous intravenous infusion for 6 weeks. Within 1 day of treatment, peripheral blood was cleared from leukemic blasts as determined by flow cytometry. The patient remained aplastic until day 15 of treatment with subsequent complete recovery of donor-derived hematopoiesis. The recovery of granulocytes was associated with a transient pulmonary infiltration and respiratory insufficiency, which resolved during the treatment with blinatumomab. After initial decrease of peripheral CD3
þ T cells at day 1 of treatment, an expansion of these cells was seen during treatment with blinatumomab with no signs of graft-versus-host disease (Figure 1b) . The bone marrow showed complete aplasia on day 15 of treatment. At the next assessment at day 28, regeneration of normal hematopoiesis without evidence of leukemia was observed. MRD-negative CR with 100% donor hematopoiesis and recovery of normal peripheral blood counts was documented on day 42 ( Figure 2b ). As side effects possibly associated with blinatumomab, fatigue (CTCAE 12) and tremor/ fasciculation of CTCAE1 1-2, both transient and completely reversible, were present during the first week of therapy. Transient arterial hypotension of CTCAE1 2 was seen within Letters to the Editor the first 2 days of treatment with complete resolution within 1 week. Although the general status of the patient improved impressively during the course of treatment, a second allogeneic HSCT was not considered because of the high cumulative toxicity of the previous treatments and the reduced clinical status. At 2 weeks after cessation of therapy, a bone marrow relapse was diagnosed and the patient died from progressive disease 3 weeks later.
The third 15-year-old patient was diagnosed with Philadelphia chromosome-positive B-precursor ALL in April 2001. After chemotherapy according to the ALL-BFM 2000 protocol, he received an allogeneic HSCT from an HLA-identical sibling in October 2001 after conditioning with total body irradiation and etoposide. In 2002, a bone marrow relapse was diagnosed and another remission was achieved with imatinib and chemotherapy by the ALL-BFM REZ protocol. He then received a second allogeneic HSCT from a 10 out of 10 HLA-identical-unrelated donor in October 2004. In March 2008, a second relapse was diagnosed and he was treated with low-dose chemotherapy and dasatinib because of the resistance to imatinib. After additional chemotherapy with clofarabine and cytosine arabinoside, the patient achieved a CR and received a third allogeneic HSCT from his three out of six HLA-allele-mismatched haploidentical father followed by post-transplant treatment with dasatinib. Because of the gastrointestinal bleeding and dilatative cardiomyopathy, dasatinib was discontinued 5 months after transplantation. In April 2009, a combined relapse in the central nervous system with 1.5 Â 10 9 /l blasts in the cerebrospinal fluid and 3% in the bone marrow was diagnosed. The patient was treated with nilotinib, intrathecal chemotherapy and fractionated irradiation of the central nervous system with 18 Gy. At 3 months after this treatment, the patient's bone marrow remained MRD positive at a level of 1.1 Â 10
À3
, whereas the central nervous system was free of blasts. Chimerism analysis of peripheral blood including T lymphocytes showed complete donor-derived hematopoiesis from his haploidentical father. The patient was then treated with blinatumomab at 15 mg/m 2 /day for 4 weeks by continuous intravenous infusion without any side effects. This patient also showed an initial decrease and subsequent expansion of lymphocytes (Figure 1c) . A bone marrow aspiration at the end of the treatment showed a CR with MRD-negative status below the quantitative detection limit of 10 À4 (Figure 2c ). At 2 weeks after the end of treatment with blinatumomab, the patient experienced a transient hemolytic episode, which was triggered by an unspecific viral infection and not causally related to blinatumomab. At 6 weeks after the end of course of blinatumomab, he received another three cycles of a 4-week course of blinatumomab at 15 mg/m 2 /day administered as continuous infusion on an outpatient basis followed by a 2-week-treatmentfree interval. There were no side effects associated with blinatumomab and the patient attended school throughout this therapy. Before each course, a bone marrow aspiration was performed and was MRD negative. At 4 weeks after the fourth course of blinatumomab, a subsequent central nervous system relapse was diagnosed and a positive MRD signal was detected in the bone marrow, although below the quantitative range of 10
À4
. The in vivo activation of donor-derived T lymphocytes using low doses of the T-cell engaging antibody blinatumomab, which can redirect T lymphocytes against CD19 þ ALL blasts is a completely new approach to the treatment of B-precursor ALL. This antibody had never been tested in any patient with relapsed B-precursor ALL after allogeneic HSCT, nor in pediatric patients. In the autologous situation, MRD responses were induced in 16 out of 20 evaluable adult patients with MRD-positive ALL as demonstrated in a phase 2 clinical trial. 7 Although our three pediatric patients had different levels of leukemia load before the treatment with blinatumomab, all three showed an impressive antileukemic response leading to MRD levels below the detection limit in bone marrow. Even circulating blasts in patient 2 were rapidly cleared. Blinatumomab administered as a continuous 24-h intravenous infusion at 15 mg/m 2 per day for several weeks was in all three patients sufficient to induce an expansion of donor-derived T lymphocytes and to eliminate leukemic blasts below the detection level of MRD. This highlights that the T-cell engaging mode of action is very different from that of conventional monoclonal antibodies, which require much higher doses and which activate other effector cells, such natural killer cells, and granulocytes via a Fc domain/Fcg receptor-mediated mechanism. Blinatumomab caused mild transient and fully reversible side effects including fatigue, mild ataxia and tremor in the first two patients. No side effects at all were seen in the third patient. The pulmonary problems of patient 2 were not attributed to the drug and most likely also not to T-cell-mediated killing of leukemic blasts in the pulmonary vasculature, since at the time of this event, the patient already had an MRD level in bone marrow below detection limit. Most likely, this event resulted from reactive pulmonary granulocyte infiltrations after recovery of the normal hematopoiesis. The continuous intravenous infusion for several weeks was well tolerated and accepted by all three patients. Two of the three patients were treated mostly on an outpatient basis.
This first clinical experience in three pediatric patients with B-precursor ALL showed that blinatumomab was well tolerated and rapidly induced MRD-negative CRs in refractory B-precursor ALL after multiple relapses and allogeneic HSCT. It is noteworthy that none of the patients showed any signs of graft-versus-host disease despite the engagement of donor-derived HLA-matched, partially matched or three-loci mismatched haploidentical T lymphocytes. These promising findings warrant clinical trials in pediatric patients with relapsed/ refractory B-precursor ALL before and after allogeneic HSCT. Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are tricarboxylic acid cycle enzymes that catalyze conversion of isocitrate to a-ketoglutarate, operating in the cytosol and mitochondria, respectively. Recently, Parsons et al. 1 described that IDH1 is mutated in 12% of glioblastomas, followed by the Yan et al.'s 2 report showing a high frequency (80%) of IDH1 mutations at the R132 residue and less frequent IDH2 mutations at the R172 residue in grade II-III gliomas and secondary glioblastomas. IDH1 and IDH2 were shown to be also mutated in 7.7-9.9% and 15.4% of acute myeloid leukemia (AML) cases, respectively, especially those having normal karyotypes. More recently, both gene mutations were found in other myeloid neoplasms, including myeloproliferative neoplasms and myelodysplastic syndrome (MDS), and were associated with a high rate of MDS-AML transformation and poor prognosis. [3] [4] [5] In hematopoietic neoplasms, all reported IDH1 mutations involved the R132 residue, while IDH2 mutations involve either the R172 or the R140 residue.
These mutations are thought to result in loss-of-function of these enzymes and prevent a-ketoglutarate production from isocitrate in a dominant-negative manner, which in turn leads to activation of the HIF-1a pathway. 6 On the other hand, Dang et al. 7 and Ward et al. demonstrated that mutant IDH1 and IDH2 also showed gain-of-function that promotes production of 2-hydroxyglutarate (2HG) from a-ketoglutarate, which is thought to be oncogenic. However, the relative contribution of loss-offunction and gain-of-function to oncogenesis is still unclear.
Here, we report mutations of both IDH1 and IDH2 in a series of 171 cases with MDS or related myeloid neoplasms, where the complete status of genome-wide copy numbers and mutations of major MDS-related genes, including c-CBL, RUNX1, TP53, FLT3ITD, JAK2, NRAS and KRAS genes, were previously investigated. 8 Our series included 28 cases with AML, 35 with chronic myelomonocytic leukemia (CMML), 3 with refractory anemia (RA), 69 with RA with excess of blasts (RAEB), 1 with RA with ringed sideroblasts (RARS), 25 with refractory cytopenia with multilineage dysplasia (RCMD), 4 with MDS-unclassified (MDS-U), and 6 with 5q-syndrome, according to the new World Health Organization classification. Mutations of IDH1 and IDH2 were examined with genomic DNA isolated from bone marrow by direct sequencing of the PCR-amplified exon 4 of both genes as previously described. 2 This study was performed under the regulation of the ethics committee at the Faculty of Medicine, University of Tokyo. Table 1 Mutational status of 16MDS or MDS-related disease with IDH mutations
